The Key To CAR-T Success Lies In Patient Selection: Are You The Ideal One?
Discover the magic of CAR-T treatment! Read our blog on patient selection for CAR T therapy. Are you the ideal candidate for this innovative cancer treatment? Find out and begin your personalized journey to cancer recovery. He..
CAR T Cells Are Reshaping the Future of Cancer Treatment!
The revolutionary CAR T Cell Therapy is changing the scenario of how we deal with cancer, making it more personal and powerful. This latest therapy uses a patient's own immune cells and genetically modifies them to target and des..
CAR - T Cell therapy, CAR T-Cell, Chimeric Agent Receptor, Korea, Seoul, South Korea
Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy
May 2023: Chimeric antigen receptor (CAR) T-cell therapy is an innovative development in the field of individualized cancer therapy. The patient's own T-cells are genetically modified during the manufacturing process to express a..
Did I Ever Tell You This, Jurassic Park, Jurassic World Dominion, Sam Neill
Sam Neill, “Jurassic Park” actor, has been diagnosed with blood cancer
March 2023: The first chapter of Sam Neill's memoir would be a tremendous shock to someone who had no prior knowledge of it. It starts out funny enough: a great yarn about his daughter Elena being questioned about her father's jo..
Clinical trials
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
March 2023: Brief Summary: The purpose of this clinical trial is to find out if anti-MESO antigen receptor CAR T-cell therapy can be used to treat epithelial ovarian cancer that has come back or stopped responding to other..
Autoimmune Diseases, clinical study, Sjogren's Syndrome
A Study of CD19/BCMA CAR-T Cells Therapy for Patients With Refractory Sjogren’s Syndrome
Detailed Description: Autoimmune diseases only show local pathological damage, but more often systemic lesions. If not diagnosed and treated in time or poorly controlled, there is a risk of disability or even death as the..
CAR T Cell therapy trials, Glioblastoma, glioblastoma trials, gliomas
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
March 2023: Study Type : Interventional (Clinical Trial)Estimated Enrollment : 30 participantsAllocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: a "3+3" design is used to determine Maximum..
CAR T Cell therapy trials, multiple myeloma trials
Clinical trial on CAR-T Cell therapy for patients with BCMA/TACI-positive relapsed and/or refractory multiple myeloma
Brief Summary: A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma Detailed Description: This is a single arm, open-label, si..
Biotechnology, CAR - T Cell therapy, CAR T-Cell, CAR therapy, China, fund raise, Oricell Therapeutics
Oricell raises additional $45M USD to expand its CAR T-Cell therapy to United States
23rd March 2023: The preclinical and early-stage cancer cell therapies being developed by Shanghai biotech Oricell have received an additional $45 million in funding, the company announced on Tuesday. Following a showing at AS..
Arcellx, CAR T Therapy, CART DDBCMA, chimeric antigen receptor, Kite Pharma, multiple myeloma
KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic..